XML 33 R7.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Cash flows from operating activities:    
Net loss $ (10,187,863) $ (22,508,304)
Adjustments to reconcile net loss to cash used in operating activities:    
Depreciation, amortization and accretion 2,591,270 4,364,680
Impairment of intangible assets 1,856,020 1,265,125
Stock-based compensation expense 348,515 2,502,092
Issuance of restricted stock 248,419 724,613
Other gain (6,277,873)
Warrants issuance and amendments 183,920 1,507
Derivative income (3,983,921) (212,809)
Amortization of prepaid research and development - related party (Note 9) 335,454
Loss on investment 61,519
Common stock issued to executives 509,996
Issuance of warrants to initial investors 596,434
Gain on sale of asset (428,374)
Changes in operating assets and liabilities:    
(Increase) in accounts receivable (50,743) (355,031)
(Increase) decrease in inventory (26,752) 195,427
(Increase) in prepaid expenses and other (129,249) (95,202)
(Decrease) increase in accounts payable and other (109,707) 493,217
(Decrease) in accrued liabilities (596,654) (414,570)
Increase (decrease) in accrued compensation 200,970 (861,226)
(Decrease) in deferred rent (6,674) (4,200)
Net cash used in operating activities (15,940,322) (13,829,652)
Cash flows used in investing activities:    
Deposit (2,200)
Purchases of fixed assets (74,707) (111,608)
Contingent consideration payment (7,385)
Purchase of assets (400,000) (6,000,000)
Investment in Acerus 1,071,707
Sale of investment in Acerus cost (91,864)
Sales of Primsol assets 1,750,000
Purchase of Primsol asset (750,000)
Cash proceed from Nuelle 613,309
Cost related to Nuelle acquisition (16,082)
Net cash used in investing activities (484,292) (3,534,538)
Cash flows from financing activities:    
Issuance of preferred, common stock and warrants 11,839,995
Issuance costs related to preferred, common stock and warrants (1,402,831)
Issuance of preferred, common stock and warrants 12,900,020
Issuance costs related to preferred, common stock and warrants (1,294,235)
Warrant exercises 677,100
S-3 registered offering cost (60,450)
Issuance of common stock to Lincoln Park 739,857
Costs related to the sale of common stock (90,924)
Warrant tender offer 2,243,282
Warrant tender offer cost (312,159)
Registered offering 8,602,499
Registered offering costs (997,865)
Over-allotment warrants purchased by placement agents 2,852
Net cash provided by financing activities 22,659,599 10,187,542
Net change in cash and cash equivalents 6,234,985 (7,176,648)
Cash and cash equivalents restricted cash at beginning of period 877,542 8,054,190
Cash and cash equivalents restricted cash at end of period 7,112,527 877,542
Warrants issued to investors and underwriters (see Note 4) 4,117,997
Warrant exercise of derivative warrants 40,096
Contingent consideration included in accounts payable 8,980
Earn-out payment to Nuelle Shareholders 250,000
Purchase of asset included in contingent consideration 293,216
Contingent consideration 2,553,169
Issuance of common stock to Nuelle share holders 1,837,500
Fixed assets included in accounts payable 10,789
Warrants issued in connection with the equity financing to the placement agents 292,630
Warrants amended in connection with warrant tender offer $ 63,182